BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC") (BIOPAC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03311776|
Recruitment Status : Recruiting
First Posted : October 17, 2017
Last Update Posted : October 17, 2017
|Condition or disease|
The overall survival of patients with pancreatic cancer (PC) is dismal and has only improved slightly during the last decades primarily due to combination chemotherapy. Early detection of PC is difficult and less than 25% of all PC patients are operated. No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers, which can be used to 1) diagnose PC early in the disease course with high specificity and sensitivity, 2) improve prognostication, or 3) predict and monitor treatment effectiveness and tolerability for the individual patient.
BIOPAC is an observational and translational open cohort study with prospective collection of biological materials and clinical data in patients with PC treated in routine care and also patients who were suspicious for malignancy in the pancreas but then operated without evidence of malignancy. Patients contribute with blood samples (i.e. serum, EDTA plasma and buffy coat, and blood in PAXgeneRNA tubes) before operation or start of adjuvant or palliative chemotherapy and during treatment with blood sampling before 2. cycle of chemotherapy and longitudinally every time of CT scan until disease progression. This schedule is repeated if patients are treated with subsequent lines of chemotherapy. The patients are followed until death. Demographics, disease characteristics, comorbidities and lifestyle factors are registered at inclusion; weight and performance status at each treatment cycle; routine blood tests (i.e. haematology, creatinine, liver enzymes, bilirubin, carbohydrate antigen 19-9, C-reactive protein); type of operation; types of chemotherapy and number of cycles given; date of disease recurrence in operated patients; date of disease progression for each line of chemotherapy; and date of death. Biomarker analyses will include a range of molecules with different characteristics such as DNA, Single Nucleotide Polymorphism (SNPs), RNA, microRNA, proteins and metabolites. Data will be analysed using appropriate methods and statistical analyses.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?|
|Actual Study Start Date :||July 3, 2008|
|Estimated Primary Completion Date :||July 2, 2035|
|Estimated Study Completion Date :||July 2, 2035|
- Diagnostic biomarkers [ Time Frame: baseline ]Biomarker analyses include, but are not limited to a range of molecules with different characteristics such as DNA, Single Nucleotide Polymorphism (SNPs), RNA, microRNA, proteins and metabolites.
- Prognostic biomarkers [ Time Frame: baseline and through study completion, an average of 1 year ]Biomarker analyses include, but are not limited to a range of molecules with different characteristics such as DNA, Single Nucleotide Polymorphism (SNPs), RNA, microRNA, proteins and metabolites.
- Predictive biomarkers [ Time Frame: baseline and through study completion, an average of 1 year ]Biomarker analyses include, but are not limited to a range of molecules with different characteristics such as DNA, Single Nucleotide Polymorphism (SNPs), RNA, microRNA, proteins and metabolites.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03311776
|Contact: Julia Sidenius Johansen, MD, DMsc||+45 38689241||Julia.Sidenius.Johansen@regionh.dk|
|Contact: Inna Markovna Chen, MD||+45 38682898||Inna.Chen@regionh.dk|
|Herlev & Gentofte Hospital||Recruiting|
|Herlev, Denmark, 2730|
|Contact: Julia Sidenius Johansen, MD, DMsc +45 38689241 Julia.Sidenius.Johansen@regionh.dk|
|Contact: Inna Markovna Chen, MD +45 38682898 Inna.Chen@regionh.dk|